DormoTech introduced DormoVision X, a wireless, AI-powered home sleep testing platform, during the SLEEP 2025 annual meeting in Seattle. The system is being marketed under a new name but is based on the DormoTech Nlab device, which received FDA clearance in December 2024.
About DormoVision X
DormoVision X is a cloud-based sleep diagnostics platform that enables remote management of both in-lab and home polysomnography. The system streams real-time physiological data and records 29 direct channels and nine derived signals. It is self-applied and does not require installation or nasal cannulas.
The platform includes a mobile app to guide patients through the sleep test and allows clinicians to monitor studies remotely. According to DormoTech, the device is designed for extended monitoring over multiple nights and is compatible with all sleep study types.
The device was cleared by the U.S. Food and Drug Administration under the name “DormoTech Nlab.” The clearance applies to use in patients age 6 and older in both supervised and unsupervised environments. According to the FDA documentation, the system includes a wearable headband with sensors for EEG, EOG, airflow, Sp02, heart rate and snoring, along with belts measuring respiratory effort and body position, an ExG unit with three electrodes, and a central unit to receive, store and transmit data.
A validation study published in Sleep and Breathing found agreement between the device and traditional polysomnography in measurements of AHI severity and complex sleep stage scoring.
DormoTech reports that the platform is built for seamless integration with the new home PSG CPT codes. The system includes AI-supported data analysis and a customizable reporting module.
Read more industry news from the AASM.
